Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 387; číslo 2; s. 132 - 147
Hlavní autoři:	Richardson, Paul G., Jacobus, Susanna J., Weller, Edie A., Hassoun, Hani, Lonial, Sagar, Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Libby, Edward N., Voorhees, Peter M., Orlowski, Robert Z., Anderson, Larry D., Zonder, Jeffrey A., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E., Khan, Abdullah M., Hurd, David D., Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Cornell, R. Frank, Hashmi, Hamza, Campagnaro, Erica L., Andreescu, Astrid C., Gentile, Teresa, Liedtke, Michaela, Godby, Kelly N., Cohen, Adam D., Openshaw, Thomas H., Pasquini, Marcelo C., Giralt, Sergio A., Kaufman, Jonathan L., Yee, Andrew J., Scott, Emma, Torka, Pallawi, Foley, Amy, Fulciniti, Mariateresa, Hebert, Kyle, Samur, Mehmet K., Masone, Kelly, Maglio, Michelle E., Zeytoonjian, Andrea A., Nadeem, Omar, Schlossman, Robert L., Laubach, Jacob P., Paba-Prada, Claudia, Ghobrial, Irene M., Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Anderson, Kenneth C., Munshi, Nikhil C.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 14.07.2022
Témata:	Adult Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Bone marrow Bone Marrow Transplantation Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Cancer Confidence intervals Dexamethasone Dexamethasone - administration & dosage Dexamethasone - adverse effects Disease Progression Disease-Free Survival Hematology Humans Immunotherapy Inhibitor drugs Lenalidomide - administration & dosage Lenalidomide - adverse effects Leukemia Lymphoma Maintenance Chemotherapy - methods Medical prognosis Melphalan Melphalan - administration & dosage Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - surgery Oncology Patients Quality of life Stem Cell Transplantation Targeted cancer therapy Transplantation, Autologous Treatments in Oncology
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2204925